Nanoviricides (NNVC) Operating Expenses (2010 - 2026)
Nanoviricides (NNVC) posted Operating Expenses of $2.0 million for Q1 2026, down 9.09% sequentially from $2.2 million in Q4 2025, and down 9.73% YoY from $2.2 million in Q1 2025.
Nanoviricides (NNVC) Operating Expenses (2010 - 2026) Analysis & Trends
Nanoviricides has reported Operating Expenses for 17 years, with the latest figure at $2.0 million in Q1 2026.
- Quarterly Operating Expenses fell 9.73% year-over-year to $2.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.2 million (down 17.14% YoY) and the FY2025 annual result came in at $9.6 million, up 12.63% from the prior year.
- Operating Expenses fell to $2.0 million in Q1 2026 per NNVC's latest filing, from $2.2 million in the prior quarter.
- Over five years, Operating Expenses peaked at $3.7 million in Q2 2023 and troughed at $1.6 million in Q3 2022.
- A 5-year average of $2.2 million and a median of $2.0 million in 2023 frame the typical range for Operating Expenses.
- The sharpest annual moves came in 2023 and 2025: Operating Expenses jumped 105.07% in 2023, then sank 43.28% in 2025.
- Over 5 years, Operating Expenses stood at $1.8 million in 2022, then grew by 19.13% to $2.2 million in 2023, then decreased by 5.75% to $2.1 million in 2024, then rose by 8.46% to $2.2 million in 2025, then slipped by 9.09% to $2.0 million in 2026.
- According to Business Quant data, Operating Expenses over the past three periods registered $2.0 million, $2.2 million, and $1.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.65 Bn | 131.79 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 86.08 Bn | 78.09 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 65.16 Bn | 59.98 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 63.25 Bn | 58.11 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 42.22 Bn | 37.12 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 31.26 Bn | 27.95 Bn | 992.69 Mn | 1.06 Bn |
| 7 | BioNTech SE | 28.96 Bn | 10.57 Bn | 668.28 Mn | -784.57 Mn |
| 8 | Insmed | 27.40 Bn | 26.24 Bn | 358.27 Mn | 427.03 Mn |
| 9 | Royalty Pharma | 27.19 Bn | 26.35 Bn | - | 541.02 Mn |
| 10 | Nanoviricides | 29.58 Mn | 26.37 Mn | - | 2.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.03 Mn |
| Dec 31, 2025 | 2.23 Mn |
| Sep 30, 2025 | 1.80 Mn |
| Jun 30, 2025 | 2.12 Mn |
| Mar 31, 2025 | 2.25 Mn |
| Dec 31, 2024 | 2.06 Mn |
| Sep 30, 2024 | 3.17 Mn |
| Jun 30, 2024 | 2.39 Mn |
| Mar 31, 2024 | 1.91 Mn |
| Dec 31, 2023 | 2.18 Mn |
| Sep 30, 2023 | 2.03 Mn |
| Jun 30, 2023 | 3.68 Mn |
| Mar 31, 2023 | 1.81 Mn |
| Dec 31, 2022 | 1.83 Mn |
| Sep 30, 2022 | 1.62 Mn |
| Jun 30, 2022 | 1.79 Mn |
| Mar 31, 2022 | 1.79 Mn |
| Dec 31, 2021 | 1.92 Mn |
| Sep 30, 2021 | 2.61 Mn |
| Jun 30, 2021 | 2.07 Mn |